In light of recent U.S. and European regulatory approvals of a dispersible version of pediatric DTG, amfAR’s TREAT Asia program recommends steps that national HIV programs and advocacy groups can take in order to secure access to this medicine as quickly as possible.
Read the brief in full here.
Source: https://www.amfar.org/news/treat-asia-calls-for-expanded-access-to-pediatric-dolutegravir/